Postprandial Decrease in LDL-cholesterol in Men with Metabolic Syndrome

Overview

Journal Open Med (Wars)

Specialty General Medicine

Date 2017 Mar 30

PMID 28352689

Citations 4

Authors

Anna Skoczynska

Barbara Turczyn

Anna Wojakowska

Boguslawa Kreczynska

Marta Skoczynska

Kamila Wojtas

Affiliations

Soon will be listed here.

Abstract

Background: In some epidemiological studies, blood lipids are determined at non-fasting state, which may impact cardiovascular risk estimation. The aim of this study was to evaluate postprandial LDL-C changes in men with newly diagnosed metabolic syndrome (MetSy).

Methods: 36 male patients were examined: 12 men with and 24 men without MetSy. The fat tolerance test was performed before and after a three-month hypolipidemic treatment. Serum lipids were measured using routine methods, lipid peroxides (LPO) colorimetrically, apolipoproteins A-I, B, and hsCRP immunoturbidimetrically.

Results: The postprandial increase in triglycerides was associated with a decrease in LDL-C and a small decrease in apo B. In men with MetSy, the mean change in LDL-C (-19.5 ± 2.3 mg/dl) was greater than in healthy men (-5.7 ± 3.8 mg/dl). All lipid changes (ΔTG, ΔLDL-C and ΔLPO) were linearly dependent on the postprandial non-LDL-cholesterol. After three months of hypolipidemic treatment, in all men with MetSy, the apoB/apoA-I ratio remained the same as before the therapy.

Conclusion: In men diagnosed with MetSy, postprandial decreases in LDL-cholesterol may cause underestimation of cardiovascular risk. After three months of hypolipidemic treatment, there was only a partial reduction in this risk, as the apoB/apoA-I ratio remained the same.

Citing Articles

Acute Antiplatelet Effects of an Oleocanthal-Rich Olive Oil in Type II Diabetic Patients: A Postprandial Study.

Katsa M, Ketselidi K, Kalliostra M, Ioannidis A, Gil A, Diamantakos P Int J Mol Sci. 2024; 25(2).

PMID: 38255980 PMC: 10815739. DOI: 10.3390/ijms25020908.

β-Cell function during a high-fat meal in young versus old adults: role of exercise.

Malin S, Frick H, Wisseman W, Edwards E, Edwards D, Emerson S Am J Physiol Regul Integr Comp Physiol. 2023; 325(2):R164-R171.

PMID: 37306399 PMC: 10393366. DOI: 10.1152/ajpregu.00047.2023.

The Role of Fasting LDL-C Levels in Their Non-fasting Reduction in Patients With Coronary Heart Disease.

Lin Q, Fu Y, Zang X, Liu Q, Liu L Front Cardiovasc Med. 2021; 8:686234.

PMID: 34222380 PMC: 8241924. DOI: 10.3389/fcvm.2021.686234.

Acute Epigallocatechin-3-Gallate Supplementation Alters Postprandial Lipids after a Fast-Food Meal in Healthy Young Women: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.

de Morais Junior A, Schincaglia R, Passarelli M, Pimentel G, Mota J Nutrients. 2020; 12(9).

PMID: 32825556 PMC: 7551107. DOI: 10.3390/nu12092533.

References

Tzou W, Douglas P, Srinivasan S, Chen W, Berenson G, Stein J . Advanced lipoprotein testing does not improve identification of subclinical atherosclerosis in young adults: the Bogalusa Heart Study. Ann Intern Med. 2005; 142(9):742-50. DOI: 10.7326/0003-4819-142-9-200505030-00009. View

Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M . Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24(4):683-9. DOI: 10.2337/diacare.24.4.683. View

Onat A, Can G, Yuksel H . Dysfunction of high-density lipoprotein and its apolipoproteins: new mechanisms underlying cardiometabolic risk in the population at large. Turk Kardiyol Dern Ars. 2012; 40(4):368-85. DOI: 10.5543/tkda.2012.55490. View

Li J, Flammer A, Lennon R, Nelson R, Gulati R, Friedman P . Comparison of the effect of the metabolic syndrome and multiple traditional cardiovascular risk factors on vascular function. Mayo Clin Proc. 2012; 87(10):968-75. PMC: 3538392. DOI: 10.1016/j.mayocp.2012.07.004. View

Grundy S . Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol. 2002; 90(8A):11i-21i. DOI: 10.1016/s0002-9149(02)02631-0. View

Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman M . Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004; 89(10):4963-71. DOI: 10.1210/jc.2004-0305. View

Yuan G, Al-Shali K, Hegele R . Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007; 176(8):1113-20. PMC: 1839776. DOI: 10.1503/cmaj.060963. View

Achimastos A, Efstathiou S, Christoforatos T, Panagiotou T, Stergiou G, Mountokalakis T . Arterial stiffness: determinants and relationship to the metabolic syndrome. Angiology. 2007; 58(1):11-20. DOI: 10.1177/0003319706295477. View

Kolovou G, Mikhailidis D, Kovar J, Lairon D, Nordestgaard B, Ooi T . Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol. 2011; 9(3):258-70. DOI: 10.2174/157016111795495549. View

10.

Contois J, Warnick G, Sniderman A . Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. J Clin Lipidol. 2011; 5(4):264-72. DOI: 10.1016/j.jacl.2011.05.004. View

11.

Spiteller G . The relation of lipid peroxidation processes with atherogenesis: a new theory on atherogenesis. Mol Nutr Food Res. 2005; 49(11):999-1013. DOI: 10.1002/mnfr.200500055. View

12.

Mottillo S, Filion K, Genest J, Joseph L, Pilote L, Poirier P . The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 56(14):1113-32. DOI: 10.1016/j.jacc.2010.05.034. View

13.

Stancliffe R, Thorpe T, Zemel M . Dairy attentuates oxidative and inflammatory stress in metabolic syndrome. Am J Clin Nutr. 2011; 94(2):422-30. PMC: 3142721. DOI: 10.3945/ajcn.111.013342. View

14.

Walldius G, Aastveit A, Jungner I . Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med. 2006; 259(3):259-66. DOI: 10.1111/j.1365-2796.2005.01610.x. View

15.

Stone N, Saxon D . Approach to treatment of the patient with metabolic syndrome: lifestyle therapy. Am J Cardiol. 2005; 96(4A):15E-21E. DOI: 10.1016/j.amjcard.2005.05.010. View

16.

Fruchart J, Duriez P . Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006; 42(1):39-64. DOI: 10.1358/dot.2006.42.1.963528. View

17.

Calabro P, Yeh E . Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr Hypertens Rep. 2008; 10(1):32-8. DOI: 10.1007/s11906-008-0008-z. View

18.

Salazar M, Carbajal H, Espeche W, Leiva Sisnieguez C, Balbin E, Dulbecco C . Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. Am J Cardiol. 2012; 109(12):1749-53. DOI: 10.1016/j.amjcard.2012.02.016. View

19.

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

20.

Nordestgaard B, Freiberg J . Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol. Curr Vasc Pharmacol. 2011; 9(3):281-6. DOI: 10.2174/157016111795495585. View